

Title (en)

PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF

Title (de)

PYRIDINDERIVATE, DEREN HERSTELLUNG UND THERAPEUTISCHE ANWENDUNG

Title (fr)

DERIVES DE PYRIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE

Publication

EP 1805143 A1 20070711 (FR)

Application

EP 05809571 A 20051017

Priority

- FR 2005002566 W 20051017
- FR 0411030 A 20041018

Abstract (en)

[origin: WO2006042955A1] The invention relates to compounds of formula (I), wherein Z is a N(R₁)XR₂,_{N(R₁)COOR'₂ or OCON(R₁)R'₂ group; X is a -CO-, -SO₂-, -CON(R₁₀)- or -CSN(R₁₀)-; R₁ is a hydrogen atom or an (C₁1}-C₄) alkyl group; R₂ is a (C<SUB>3-C₁₀) alkyl group, a (C₃-C₁₂) carboxylic non-aromatic radical, a heterocyclic radical, a non-substituted or substituted phenyl and a (C₁-C₂) alkylene substituted by one or two equal or different substituents; R₃ is a hydrogen atom, or a (C₁-C₄) alkyl, cyano, (C₁-C₄) alkoxyethyl or hydroxymethyl group. The inventive method can be used for preparing and therapeutically using said compounds.

IPC 8 full level

C07D 213/06 (2006.01)

CPC (source: EP KR US)

A61K 31/44 (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/08** (2017.12 - EP); **A61P 1/12** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/00** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/02** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 25/32** (2017.12 - EP); **A61P 25/34** (2017.12 - EP); **A61P 27/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 29/02** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C07D 209/12** (2013.01 - KR); **C07D 213/06** (2013.01 - KR); **C07D 213/40** (2013.01 - EP US); **C07D 213/42** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP KR US)

Citation (search report)

See references of WO 2006042955A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

FR 2876691 A1 20060421; FR 2876691 B1 20061229; AR 051221 A1 20061227; AU 2005296959 A1 20060427; BR PI0516926 A 20080923; CA 2582778 A1 20060427; CN 101039912 A 20070919; EA 200700891 A1 20070831; EC SP077400 A 20070530; EP 1805143 A1 20070711; IL 182385 A0 20070724; JP 2008516934 A 20080522; KR 20070063008 A 20070618; MA 29016 B1 20071101; MX 2007004482 A 20070613; NO 20072454 L 20070514; NZ 554952 A 20090828; PE 20060584 A1 20060818; TN SN07114 A1 20080602; TW 200628450 A 20060816; US 2008021070 A1 20080124; UY 29163 A1 20060428; WO 2006042955 A1 20060427

DOCDB simple family (application)

FR 0411030 A 20041018; AR P050104331 A 20051017; AU 2005296959 A 20051017; BR PI0516926 A 20051017; CA 2582778 A 20051017; CN 200580035437 A 20051017; EA 200700891 A 20051017; EC SP077400 A 20070417; EP 05809571 A 20051017; **FR 2005002566 W 20051017;** IL 18238507 A 20070401; JP 2007536229 A 20051017; KR 20077008717 A 20070417; MA 29893 A 20070511; MX 2007004482 A 20051017; NO 20072454 A 20070514; NZ 55495205 A 20051017; PE 2005001213 A 20051014; TN SN07114 A 20070328; TW 94136199 A 20051017; US 69577007 A 20070403; UY 29163 A 20051014